Biocept, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIOC research report →
Companybiocept.com
Biocept, Inc. , a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms.
- CEO
- Darrell Taylor
- IPO
- 2014
- Employees
- 50
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $450.79K
- P/E
- -0.01
- P/S
- 0.02
- P/B
- 0.03
- EV/EBITDA
- 0.01
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -9.99%
- Op Margin
- -123.69%
- Net Margin
- -124.09%
- ROE
- -138.49%
- ROIC
- -117.56%
Growth & Income
- Revenue
- $25.86M · -57.78%
- Net Income
- $-32,087,000 · -1036.23%
- EPS
- $-56.78 · -890.92%
- Op Income
- $-31,983,000
- FCF YoY
- -765.53%
Performance & Tape
- 52W High
- $0.49
- 52W Low
- $0.43
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.59
- Avg Volume
- 0
Get TickerSpark's AI analysis on BIOC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 16, 23 | Walsh Robert | other | 806 |
| Nov 17, 22 | DAO-HADDOCK QUYEN THI | other | 10,000 |
| Nov 17, 22 | DAO-HADDOCK QUYEN THI | other | 0 |
| Nov 17, 22 | DAO-HADDOCK QUYEN THI | other | 0 |
| Jul 8, 22 | Chandler Marsha Alpert | other | 10,000 |
| Jul 8, 22 | Chandler Marsha Alpert | other | 10,000 |
| Jul 8, 22 | Rubinstein Linda M | other | 10,000 |
| Jul 8, 22 | Gerhardt Bruce | other | 10,000 |
| Jul 8, 22 | ROYSTON IVOR | other | 10,000 |
| Jul 8, 22 | ROYSTON IVOR | other | 10,000 |
Our BIOC Coverage
We haven't published any research on BIOC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BIOC Report →